Meloxicam Microgranule Formulation for Rapid Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a poorly soluble NSAID, faces challenges with slow dissolution and absorption due to low water solubility, leading to undesirable pharmacokinetic properties and safety concerns, particularly in oral and intravenous administration.
Innovation Solution
Development of unit dosage forms of meloxicam with particle sizes between 100 nm and 5000 nm, achieving rapid dissolution within 5-30 minutes, and providing effective pain relief with lower systemic exposure through formulations of 5 mg and 10 mg doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If meloxicam is administered in conventional tablet form, then the dosage can be maintained at standard levels (7.5-15 mg), but the dissolution rate is slow and absorption is delayed due to poor water solubility
Solution Approach 1:
The meloxicam tablet is segmented into multiple microgranules, each containing a small amount of meloxicam (e.g., 0.5-2 mg per microgranule). This segmentation increases the total surface area of the drug particles, thereby accelerating the dissolution rate while maintaining the total dosage. The microgranules are further coated with enteric coating material to control release and improve absorption reliability.
Solution Approach 2:
Different regions of the tablet structure are assigned different functional properties. The core microgranules contain the drug substance with high surface area for rapid dissolution, while the outer coating layers provide controlled release and protect against premature dissolution. This local differentiation of properties optimizes both dissolution speed and pharmacokinetic reliability.
2Object-affected harmful factors
If the dosage of meloxicam is reduced to lower systemic exposure, then side effects are reduced, but the therapeutic efficacy may be compromised
Solution Approach 1:
The tablet is divided into multiple microgranules, each contributing to the overall therapeutic effect. This segmentation allows for better distribution of the drug in the gastrointestinal tract, improving absorption efficiency and ensuring that the reduced dosage still achieves the necessary therapeutic plasma concentrations while minimizing peak-related side effects.
Solution Approach 2:
The microgranules are pre-coated with enteric coating material during manufacturing, which protects the drug from degradation in the stomach and ensures release in the intestine where absorption is optimal. This preliminary protective action enhances the reliability of therapeutic efficacy even at lower dosages by maximizing bioavailability.
3Speed
If particle size of meloxicam is decreased to increase surface area, then dissolution rate improves, but manufacturing complexity increases
Solution Approach 1:
The manufacturing process utilizes self-service mechanisms where the meloxicam powder is directly granulated into microgranules using minimal external intervention. The granulation process itself generates the desired particle size distribution, and the enteric coating is applied in a continuous manner during the same manufacturing line, reducing the need for separate complex processing steps.
Solution Approach 2:
The manufacturing process controls particle size by adjusting parameters such as granulation speed, binder concentration, and drying conditions rather than using multiple size-reduction steps. This parameter-based control achieves the desired fine particle size distribution while keeping the manufacturing process relatively simple and scalable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations exhibit rapid absorption and lower systemic exposure, offering effective pain relief for conditions like osteoarthritis with reduced side effects and improved safety profiles compared to conventional meloxicam tablets.
Implementation Method 1
The formulations exhibit rapid absorption and lower systemic exposure
Data Source
AI summary
Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.